Peddie B A, Bailey R R, Blake E, Summerfield M J
N Z Med J. 1980 May 28;91(660):378-81.
Netilmicin is a new aminoglycoside antibiotic with pharmacological similarities to gentamicin, tobramycin and sisomicin. Fourteen of 15 patients with a severe or complicated urinary tract infection were cured by treatment with a seven day course of netilmicin. In one patient the infecting organism was not eradicated. No significant side effects were noted and no ototoxicity was detected. Four patients had a significant, but reversible, deterioration in renal function as defined by an increase in the plasma creatinine of 0.03 mmol/l or greater. Work in experimental animals has shown netilmicin to be significantly less ototoxic and nephrotoxic than other clinically available aminoglycosides. If this finding is confirmed in large-scale comparative trials in man, netilmicin should prove a most useful and effective new antibiotic for the treatment of severe gram-negative sepsis.
奈替米星是一种新型氨基糖苷类抗生素,在药理学上与庆大霉素、妥布霉素和西索米星相似。15例患有严重或复杂性尿路感染的患者中,有14例通过接受为期7天的奈替米星治疗而治愈。有1例患者的感染病原体未被根除。未观察到明显的副作用,也未检测到耳毒性。有4例患者的肾功能出现了显著但可逆的恶化,定义为血浆肌酐升高0.03 mmol/l或更高。对实验动物的研究表明,奈替米星的耳毒性和肾毒性明显低于其他临床可用的氨基糖苷类抗生素。如果这一发现能在大规模的人体对比试验中得到证实,奈替米星将被证明是治疗严重革兰氏阴性菌败血症最有用且有效的新型抗生素。